Пређи на садржај

CXCL1

С Википедије, слободне енциклопедије
Hemokin (C-X-C motiv) ligand 1 (melanom rast stimulišuća aktivnost, alfa)
PDB prikaz baziran na 1mgs​.
Dostupne strukture
1mgs​, 1msg​, 1msh
Identifikatori
Simboli CXCL1; GRO1; GROa; MGSA; MGSA alpha; MGSA-a; NAP-3; SCYB1
Vanjski ID OMIM155730 MGI3037818 HomoloGene84701 GeneCards: CXCL1 Gene
Ortolozi
Vrsta Čovek Miš
Entrez 2919 330122
Ensembl ENSG00000163739 ENSMUSG00000029379
UniProt P09341 n/a
RefSeq (mRNA) NM_001511 NM_203320
RefSeq (protein) NP_001502 NP_976065
Lokacija (UCSC) Chr 4:
74.95 - 74.97 Mb
Chr 5:
91.86 - 91.86 Mb
PubMed pretraga [1] [2]

CXCL1, hemokin (C-X-C motiv) ligand 1, je mali citokin koji pripada CXC hemokin familiji. On se ranije zvao GRO1 onkogen, GROα, KC, neutrofil-aktivirajući protein 3 (NAP-3) i melanoma rast stimulišuća aktivnost, alfa (MSGA-α). Kod ljudi, ovaj protein je kodiran CXCL1 genom.[1][2]

CXCL1 izlučuju ljudske ćelije melanoma. On ima mitogene osobine i učestvuje u patogenezi melanoma.[3][4] CXCL1 izražavaju makrofage, neutrofili i epitelske ćelije,[5][6] i dejstvuje kao neutrofilni hemoatraktant.[7][8] CXCL1 igra ulogu u razvoju kičmene moždine putem inhibicije migracije oligodendrocit prekurzora, i učestvuje u procesima angiogeneze, inflamacije, zarastanja rana, i tumorigeneze.[9][10][11][12]

Ovaj hemokin dejstvuje putem signaliziranja kroz hemokin receptor CXCR2.[9] Gen za CXCL1 je lociran na ljudskom hromozomu 4 među genima za drugih CXC hemokina.[13] Jedna početna studija na miševima je proizvela evidenciju da CXCL1 umanjuje težinu multiple skleroze i da možda može da ima neuroprotektivnu ulogu.[14]

  1. ^ Haskill S, Peace A, Morris J, Sporn SA, Anisowicz A, Lee SW, Smith T, Martin G, Ralph P, Sager R (1990). „Identification of three related human GRO genes encoding cytokine functions”. Proc. Natl. Acad. Sci. U.S.A. 87 (19): 7732—6. PMC 54822Слободан приступ. PMID 2217207. doi:10.1073/pnas.87.19.7732. 
  2. ^ Mire-Sluis, Anthony R.; Thorpe, Robin, ур. (1998). Cytokines (Handbook of Immunopharmacology). Boston: Academic Press. ISBN 0-12-498340-5. 
  3. ^ Anisowicz A, Bardwell L, Sager R (1987). „Constitutive overexpression of a growth-regulated gene in transformed Chinese hamster and human cells”. Proc. Natl. Acad. Sci. U.S.A. 84 (20): 7188—92. PMC 299255Слободан приступ. PMID 2890161. doi:10.1073/pnas.84.20.7188. 
  4. ^ Richmond A, Thomas HG (1988). „Melanoma growth stimulatory activity: isolation from human melanoma tumors and characterization of tissue distribution”. J. Cell. Biochem. 36 (2): 185—98. PMID 3356754. doi:10.1002/jcb.240360209. 
  5. ^ Iida N, Grotendorst GR (1990). „Cloning and sequencing of a new gro transcript from activated human monocytes: expression in leukocytes and wound tissue”. Mol. Cell. Biol. 10 (10): 5596—9. PMC 361282Слободан приступ. PMID 2078213. 
  6. ^ Becker S, Quay J, Koren HS, Haskill JS (1994). „Constitutive and stimulated MCP-1, GRO alpha, beta, and gamma expression in human airway epithelium and bronchoalveolar macrophages”. Am. J. Physiol. 266 (3 Pt 1): L278—86. PMID 8166297. [мртва веза]
  7. ^ Moser B, Clark-Lewis I, Zwahlen R, Baggiolini M (1990). „Neutrophil-activating properties of the melanoma growth-stimulatory activity”. J. Exp. Med. 171 (5): 1797—802. PMC 2187876Слободан приступ. PMID 2185333. doi:10.1084/jem.171.5.1797. 
  8. ^ Schumacher C, Clark-Lewis I, Baggiolini M, Moser B (1992). „High- and low-affinity binding of GRO alpha and neutrophil-activating peptide 2 to interleukin 8 receptors on human neutrophils”. Proc. Natl. Acad. Sci. U.S.A. 89 (21): 10542—6. PMC 50375Слободан приступ. PMID 1438244. doi:10.1073/pnas.89.21.10542. 
  9. ^ а б Tsai HH, Frost E, To V, Robinson S, Ffrench-Constant C, Geertman R, Ransohoff RM, Miller RH (2002). „The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration”. Cell. 110 (3): 373—83. PMID 12176324. doi:10.1016/S0092-8674(02)00838-3. 
  10. ^ Devalaraja RM, Nanney LB, Du J, Qian Q, Yu Y, Devalaraja MN, Richmond A (2000). „Delayed wound healing in CXCR2 knockout mice”. J. Invest. Dermatol. 115 (2): 234—44. PMC 2664868Слободан приступ. PMID 10951241. doi:10.1046/j.1523-1747.2000.00034.x. 
  11. ^ Haghnegahdar H, Du J, Wang D, Strieter RM, Burdick MD, Nanney LB, Cardwell N, Luan J, Shattuck-Brandt R, Richmond A (2000). „The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma”. J. Leukoc. Biol. 67 (1): 53—62. PMC 2669312Слободан приступ. PMID 10647998. [мртва веза]
  12. ^ Owen JD, Strieter R, Burdick M, Haghnegahdar H, Nanney L, Shattuck-Brandt R, Richmond A (1997). „Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine beta and gamma proteins”. Int. J. Cancer. 73 (1): 94—103. PMID 9334815. doi:10.1002/(SICI)1097-0215(19970926)73:1<94::AID-IJC15>3.0.CO;2-5. 
  13. ^ Richmond A, Balentien E, Thomas HG, Flaggs G, Barton DE, Spiess J, Bordoni R, Francke U, Derynck R (1988). „Molecular characterization and chromosomal mapping of melanoma growth stimulatory activity, a growth factor structurally related to beta-thromboglobulin”. EMBO J. 7 (7): 2025—33. PMC 454478Слободан приступ. PMID 2970963. 
  14. ^ Omari KM, Lutz SE, Santambrogio L, Lira SA, Raine CS (2009). „Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1”. Am. J. Pathol. 174 (1): 164—76. PMC 2631329Слободан приступ. PMID 19095949. doi:10.2353/ajpath.2009.080350.